about
Primary hepatic carcinoid tumoursGlaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinasesThe apoptotic response of liver and colorectal liver metastases to focal hyperthermic injury.Effect of blood flow occlusion on laser hyperthermia for liver metastases.Interstitial laser thermotherapy in the treatment of colorectal liver metastases.Effect of interstitial laser hyperthermia in a murine model of colorectal liver metastases.Interstitial laser thermotherapy for liver tumours.Effect of interstitial laser hyperthermia in a murine model of colorectal liver metastases: scanning electron microscopic study.Focal hyperthermia produces progressive tumor necrosis independent of the initial thermal effects.Progressive microvascular injury in liver and colorectal liver metastases following laser induced focal hyperthermia therapy.Patterns of heat shock protein (HSP70) expression and Kupffer cell activity following thermal ablation of liver and colorectal liver metastases.Effect of thalidomide on colorectal cancer liver metastases in CBA mice.Altered growth patterns of colorectal liver metastases after thermal ablation.Impact of blood flow occlusion on liver necrosis following thermal ablation.Alterations in vascular architecture and permeability following OXi4503 treatment.Changes in the renin angiotensin system during the development of colorectal cancer liver metastases.The impact of fluid intervention on complications and length of hospital stay after pancreaticoduodenectomy (Whipple's procedure)The treatment of malignancy by hyperthermia.Changes in growth factor levels after thermal ablation in a murine model of colorectal liver metastasesCirculating alanine transaminase (ALT) and γ-glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus Metabolism Study.Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation.Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments.Development of an international online learning platform for hepatopancreatobiliary surgical training: a needs assessment.Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies.From minimal to maximal surgery in the treatment of hepatocarcinoma: A reviewWhat determines ageing of the transplanted liver?Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.Steroid Sex Hormones, Sex Hormone-Binding Globulin, and Diabetes Incidence in the Diabetes Prevention Program.Disturbances of the microcirculation in acute pancreatitis.Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forcesPotential effects of hyperbaric oxygen therapy in acute pancreatitis.Hyperbaric oxygen therapy for malignancy: a review.Characterization of an animal model of hepatic metastasis.Liver regeneration and tumor stimulation--a review of cytokine and angiogenic factors.Selective targeting of the tumour vasculature.Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor.Restrictive versus liberal fluid therapy in major abdominal surgery (RELIEF): rationale and design for a multicentre randomised trialAneurysms of the splenic artery - a review.Liver regeneration and tumour stimulation: implications of the renin-angiotensin system.
P50
Q28272261-B11982F5-9159-497A-A88B-5172D0EDF1C5Q28307180-43AB9B5B-9BFF-425D-890C-C72F201207B1Q30783113-BE22A37B-83EB-4DEB-84C9-20480D8BA73AQ30829087-7B497273-AAD3-40BD-BEB4-BE77EB12E9FEQ30982302-BD0BAC88-243E-475B-A93B-2D7B2C0111C4Q31089300-10ABC942-18A7-4133-8DBC-116EB018A4A7Q31155171-BF3B55E0-58BB-4C1D-AC8E-98AAA15C477FQ33195492-41AC67BA-92D1-47E3-9C66-E19730A11FECQ33212569-0ECB0E61-DD13-4B96-8CDE-7B3F623859CEQ33217046-506973EE-3D6E-4392-B8D7-3130D5A9FD26Q33219522-B0EC2D82-5C49-4AA9-982A-A3BC04EA5861Q33219853-952EEB8C-9707-44AC-8CBE-781E279D445CQ33229907-F731205F-2D11-4839-911C-A74B3FCDFD0EQ33234134-A8D67E2A-CAF2-4DF8-8D2F-0ABA9EFD6149Q33307486-8222B558-79CC-449A-838C-B8C260CDE861Q33551485-9E316337-BC0F-421E-ADA0-5D0F2DDF0009Q33623773-602AF1DB-B79A-4520-AEE9-631CD4643468Q33696552-EFCDEDA1-03FC-43CD-8662-8CA02B1960C4Q33850209-112C982B-41E6-4F5A-8CB4-8856775642D9Q33924942-5DBDA3DB-4A82-4A8D-B536-244089C27810Q33942508-4447F027-FDF1-4B08-979A-71DD3C4D73D4Q34478450-E337BB9E-7EF2-4651-9DCF-364C7D401074Q34618759-77470691-CD57-4CCC-A732-C0E38CD38D60Q34660246-5A9DC0DF-156A-4B61-A1E8-45C84AA09357Q34966860-80163267-91D3-44E6-8F3A-AB220298F9DFQ35099245-64547180-B034-4BE5-A9C6-8FB49AE2B784Q35764682-86EB9B0A-B06F-4D1C-A5A3-F0E175578645Q36086593-5902BBC9-2155-446E-8B3D-CD08DAE81C15Q36129822-42232800-A136-4B2D-8D5E-31161AD5BFEBQ36445364-80977174-A4F0-4355-9AD7-0656BFCC8221Q36507245-E7504384-04BA-469F-8BB3-5EF7E64AE52CQ36524408-E82C150C-5A43-4AD7-99A4-BBD65759F50AQ36653195-69FC1B94-6686-41CA-A5CF-3478FE58E582Q36803982-D2909031-09B6-4721-AC2E-F39925732D0BQ37052713-0A681E15-22BF-47C0-B9CB-634A5C6103C3Q37311351-D1D9659D-4603-4A53-90B3-1C98DBF56AEDQ37482536-07B2BA11-2264-44AE-B607-9535B630522DQ37704213-9B71E19F-311C-488C-B7D0-88238201ABD0Q37766999-2DA76CB1-5041-4C77-B7A5-160D4C0DE661Q37772958-E432D631-266E-4AA3-9E67-EDC50AEB3DA1
P50
description
researcher ORCID ID = 0000-0002-1349-0884
@en
wetenschapper
@nl
name
Christopher Christophi
@ast
Christopher Christophi
@en
Christopher Christophi
@es
Christopher Christophi
@nl
type
label
Christopher Christophi
@ast
Christopher Christophi
@en
Christopher Christophi
@es
Christopher Christophi
@nl
prefLabel
Christopher Christophi
@ast
Christopher Christophi
@en
Christopher Christophi
@es
Christopher Christophi
@nl
P106
P21
P31
P496
0000-0002-1349-0884